Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

trigen laboratories, llc - ferrous fumarate (unii: r5l488ry0q) (ferrous cation - unii:gw89581owr), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii - folivane™ - plus is contraindicated in patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

cis bio international - yttrium (90y) chloride - radionuclide imaging - diagnostic radiopharmaceuticals - to be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.radiopharmaceutical precursor - not intended for direct application to patients.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

eckert ziegler radiopharma gmbh - yttrium (90y) chloride - radionuclide imaging - diagnostic radiopharmaceuticals - to be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.radiopharmaceutical precursor - not intended for direct use in patients.

Israel - engleză - Ministry of Health

amgen europe b.v. - blinatumomab - powder for concentrate for solution for infusion - blinatumomab 35 mcg / 1 vial - blinatumomab - • blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b- precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options.• blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%.• blincyto is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b-cell precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.• blincyto is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b precursor all as part of the consolidation therapy.limitations of use: after failure of two previous treatments and with no cns involvement.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - yttrium(90y) chloride -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tisagenlecleucel, quantity: 1200000 cells - suspension - excipient ingredients: glucose; sodium; chloride; albumin; aluminium; magnesium; dimethyl sulfoxide; gluconic acid; acetate; caprylate; furfural; dimethyl sulfone; dextran 40; potassium; n-acetyltryptophan - cellular therapies - kymriah is a genetically modified autologous immunocellular therapy indicated for the treatment of paediatric and young adult patients up to 25 years of age with b-cell precursor acute lymphoblastic leukaemia (all) that is refractory, in relapse post-transplant, or in second or later relapse.

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international quadratics pty ltd - chlorine dioxide - tablet (inc. pellet, bolus, suppository, capsule) - chlorine dioxide mineral-chlorine active 100.0 g/kg - pool chlorine

Israel - engleză - Ministry of Health

pfizer pharmaceuticals israel ltd - inotuzumab ozogamicin - powder for concentrate for solution for infusion - inotuzumab ozogamicin 1 mg/vial - inotuzumab ozogamicin - besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory cd22-positive b cell precursor acute lymphoblastic leukaemia (all). adult patients with philadelphia chromosome positive (ph+) relapsed or refractory b cell precursor all should have failed treatment with at least 1 tyrosine kinase inhibitor (tki).

Singapore - engleză - HSA (Health Sciences Authority)

qt instruments (s) pte ltd - lutetium (177lu) chloride - solution - lutetium (177lu) chloride 40 gbq/ml

Israel - engleză - Ministry of Health

gilead sciences israel ltd - anti-cd19 car t cells - dispersion for infusion - anti-cd19 car t cells - acute lymphoblastic leukaemia tecartus is indicated for the treatment of adult patients with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).mantle cell lymphoma tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton's tyrosine kinase (btk) inhibitor unless ineligible to btk inhibitor •limitation of use : tecartus is not indicated for the treatment of patients with active central nervous system lymphoma